Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Imprimis Phar (IMMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,892
  • Shares Outstanding, K 20,880
  • Annual Sales, $ 26,770 K
  • Annual Income, $ -11,990 K
  • 36-Month Beta -0.42
  • Price/Sales 1.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +2.87%
on 05/23/18
2.60 -17.31%
on 05/16/18
-0.07 (-3.15%)
since 04/24/18
3-Month
1.71 +25.73%
on 04/02/18
2.60 -17.31%
on 05/16/18
+0.37 (+20.79%)
since 02/23/18
52-Week
1.35 +59.26%
on 11/02/17
4.13 -47.94%
on 06/02/17
-1.35 (-38.57%)
since 05/24/17

Most Recent Stories

More News
Imprimis Pharmaceuticals Announces First Quarter 2018 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the first quarter 2018.

IMMY : 2.15 (-0.46%)
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying...

IMMY : 2.15 (-0.46%)
Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National Western Life Group, Phibro Animal Health, and Imprimis Pharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Albany International Corporation...

APTS : 14.49 (-0.69%)
NWLI : 312.00 (+1.35%)
IMMY : 2.15 (-0.46%)
AIN : 61.95 (-0.40%)
JBGS : 36.47 (-1.14%)
PAHC : 44.80 (-0.44%)
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), and its ophthalmology-focused ImprimisRx division, today announced its participation and related physician presentations at the 2018 American Society of Cataract...

IMMY : 2.15 (-0.46%)
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron)...

IMMY : 2.15 (-0.46%)
Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enbridge Energy Management...

EEQ : 9.37 (-0.53%)
HIBB : 28.95 (+1.94%)
GBCI : 39.89 (-0.70%)
IMMY : 2.15 (-0.46%)
FOXF : 39.00 (+1.17%)
RGS : 17.20 (+0.17%)
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017.

IMMY : 2.15 (-0.46%)
Wired News - Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications

Stock Monitor: Akcea Therapeutics Post Earnings Reporting

IMMY : 2.15 (-0.46%)
AKCA : 23.60 (+4.56%)
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business...

IMMY : 2.15 (-0.46%)
Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday,...

IMMY : 2.15 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMMY with:

Business Summary

Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.

See More

Key Turning Points

2nd Resistance Point 2.28
1st Resistance Point 2.22
Last Price 2.15
1st Support Level 2.10
2nd Support Level 2.04

See More

52-Week High 4.13
Fibonacci 61.8% 3.07
Fibonacci 50% 2.74
Fibonacci 38.2% 2.41
Last Price 2.15
52-Week Low 1.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar